Sugi Predict

Sugi Predict / Compounds / SCHEMBL894741

SCHEMBL894741

SCHEMBL894741

CC(=O)Nc1ccccc1C(N)=O

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 1/20 0.70
▸ POLB P06746 3/20 0.65
▸ CYP2C19 P33261 1/20 0.65
▸ KDM4E B2RXH2 8/20 0.59
▸ ALDH1A1 P00352 4/20 0.57
▸ NPC1 O15118 4/20 0.57
▸ RAB9A P51151 4/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ HPGD P15428 2/20 0.57
▸ PDCD1 Q15116 1/20 0.56
▸ CD274 Q9NZQ7 1/20 0.56
▸ LMNA P02545 2/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ MAPT P10636 1/20 0.54
▸ PKM P14618 1/20 0.54
▸ MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anthranilamide SCHEMBL2985093 0.91 SIRT2 (0.60) SIRT2POLBCYP2C19KDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL3600528 0.88 SIRT2 (0.57) SIRT2POLBCYP2C19KDM4EALDH1A1
SCHEMBL5365142 0.85 KDM4E (0.65) SIRT2POLBKDM4EALDH1A1NPC1
SCHEMBL27493862 0.85 CYP2C19 (0.61) SIRT2POLBCYP2C19KDM4EALDH1A1
SCHEMBL7400861 0.85 CYP2C19 (0.61) SIRT2POLBCYP2C19KDM4EALDH1A1
Valine SCHEMBL5940586 0.84 SIRT2 (0.54) SIRT2POLBCYP2C19KDM4EALDH1A1
SCHEMBL505353 0.83 CYP2C19 (0.69) POLBCYP2C19KDM4EALDH1A1NPC1
SCHEMBL29808973 0.83 CYP2C19 (0.69) POLBCYP2C19KDM4EALDH1A1NPC1
SCHEMBL5509803 0.83 SIRT2 (0.55) SIRT2POLBCYP2C19KDM4EALDH1A1
SCHEMBL5947666 0.83 KDM4E (0.58) SIRT2POLBKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903056-A 2-Substituted acetamido benzamide derivative and application thereof in preparation of anti-influenza virus drugs 沈阳药科大学 2024-04-19 — — CN claimed
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 — — US claimed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 — — US claimed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US claimed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 — — EP claimed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 — — US claimed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 — — WO claimed
US-7005546-B2 Acetamidobenzamide compounds for neurodegenerative disorders RENOVIS, INC. (US) 2006-02-28 — — US claimed
EP-1581202-A2 METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME Renovis, Inc. (US) 2005-10-05 — — EP claimed
US-20040266881-A1 Acetamidobenzamide compounds for neurodegenerative disorders RENOVIS, INC. 2004-12-30 — — US claimed
WO-1999059569-A1 BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 1999-11-25 — — WO claimed
EP-0912171-A1 BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION CENTAUR PHARMACEUTICALS, INC. (US) 1999-05-06 — — EP claimed
EP-0858455-A1 4-OXA AND 4-THIA STEROIDS Merck & Co., Inc. (US) 1998-08-19 — — EP claimed
EP-0819113-A1 BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT CENTAUR PHARMACEUTICALS, INC. (US) 1998-01-21 — — EP claimed
WO-1997038684-A1 BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION CENTAUR PHARMACEUTICALS, INC. (US) 1997-10-23 — — WO claimed
EP-0775110-A1 ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS WARNER-LAMBERT COMPANY (US) 1997-05-28 — — EP claimed
WO-1997015564-A1 4-OXA AND 4-THIA STEROIDS MERCK & CO., INC. (US) 1997-05-01 — — WO claimed
WO-1996031462-A1 BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT CENTAUR PHARMACEUTICALS, INC. (US) 1996-10-10 — — WO claimed
WO-1996007643-A1 PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS MERCK & CO., INC. (US) 1996-03-14 — — WO claimed
WO-1996004242-A1 ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS WARNER-LAMBERT COMPANY (US) 1996-02-15 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG SIRT2 419/4885POLB 3816/4885CYP2C19 2489/4885
US-20040266881-A1 Acetamidobenzamide compounds for neurodegenerative disorders SNCA, PARK7, GBA1 SIRT2 1265/4885POLB 468/4885CYP2C19 2072/4885
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG SIRT2 419/4885POLB 3816/4885CYP2C19 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.